Daily Clinical Briefing · Educational reading for healthcare professionals
Early dexamethasone matters in bacterial meningitis, and Listeria confirmation may not mean it should stop.
If dexamethasone starts for suspected bacterial meningitis and Listeria is later identified, the cohort discussed supports completing four days.
The organism causing bacterial meningitis is often unknown when treatment needs to start. That makes adjunctive dexamethasone a timing decision before it becomes a microbiology decision.
The rationale is inflammatory. Infection itself generates inflammation, and antibiotic-induced bacterial death adds another inflammatory stimulus. Dexamethasone aims to limit that response, with the strongest benefit described for pneumococcal meningitis. In the adult study discussed, treatment with 0.15 mg/kg four times daily for four days reduced hearing loss and cognitive impairment.
Timing is central to that effect. Dexamethasone should ideally accompany or precede the first antibiotic dose. Missing that moment does not necessarily mean the opportunity has disappeared: the episode describes an early window of roughly four to twelve hours after antibiotics begin. Starting dexamethasone the following day simply to correct an earlier omission falls outside the beneficial timing described.
Listeria creates a more interesting decision.
Older teaching has favoured stopping dexamethasone once testing identifies Listeria because of concern that steroids might worsen outcomes. More recent Dutch prospective cohort data point in the opposite direction. Patients receiving early dexamethasone for the full four-day course had better outcomes, while early discontinuation was associated with worse outcomes.
That finding changes the direction of the clinical argument, but not the certainty of the evidence. This was a prospective cohort rather than a randomised trial. Listeria meningitis is sufficiently uncommon that a definitive randomised study would be difficult, so clinicians may have to make decisions from evidence that is useful without being conclusive.
There are therefore two different errors to avoid. The first is waiting for organism identification before starting dexamethasone and losing the early treatment window. The second is automatically stopping treatment when Listeria appears on molecular or microbiological testing because older teaching says that steroids are harmful.
The practical sequence is clearer than the evidence hierarchy might suggest: start dexamethasone early when treating suspected bacterial meningitis, identify the organism using appropriate testing, then interpret pathogen-specific evidence rather than treating all causes of meningitis alike. If Listeria is identified after dexamethasone has begun, the cohort discussed supports completing the four-day course rather than reflexively stopping it.
Well-studied peptide medicines differ sharply from experimental products promoted for injury recovery, muscle building and anti-ageing; assessing human evidence, regulatory approval, product purity and the specific route of administration helps separate established treatment from plausible but unproven claims.
Developing emergency care in the Eastern Cape depends on effective triage, referral pathways, locally adapted training and strong non-specialist teams, alongside collaborative leadership, workplace education and career structures that can sustain clinicians beyond better-resourced tertiary centres.
Intra-aortic balloon pumps, Impella, TandemHeart and durable left ventricular assist devices support different circulatory problems, with device position, ventricular filling, right ventricular function, suction events and the limitations of calculated flow readings shaping critical care management.
A small single-centre ICU trial finds no significant difference in seven-day delirium-and-coma-free survival between olanzapine and low-dose dexmedetomidine; an exploratory mortality signal favouring olanzapine remains insufficient to justify routine practice change.
Immune abnormalities can persist despite good metabolic control in propionic and methylmalonic acidaemia, so recurrent severe infections, unusual organisms or persistent cytopenias may justify targeted immune assessment while small pooled studies limit disease-specific conclusions.
Early dexamethasone alongside antibiotics in pneumococcal meningitis aims to limit the inflammatory response to infection and bacterial killing, with benefits for hearing and cognition dependent on giving treatment before or soon after the first antibiotic dose.
Prospective Dutch cohort data associate early, complete dexamethasone treatment with better outcomes in Listeria meningitis, challenging older advice to stop steroids once Listeria is identified while leaving important uncertainty because the evidence is observational rather than randomised.
Electroconvulsive therapy can treat treatment-resistant depression and persistent catatonia, including catatonia associated with anti-NMDA receptor encephalitis, while electrode placement, seizure monitoring, clinical response and potentially persistent retrograde memory loss shape individual treatment decisions.
When treating suspected bacterial meningitis, plan dexamethasone alongside the first antibiotic rather than waiting for organism identification. If Listeria is subsequently identified, avoid reflexively stopping the course while recognising that the supporting evidence comes from a prospective cohort rather than a randomised trial.
An adult with suspected bacterial meningitis receives the first antibiotic dose before dexamethasone is given. Six hours later the omission is recognised. Does the timing described mean the opportunity for adjunctive dexamethasone has necessarily passed?
No. The material describes an early window of approximately four to twelve hours after antibiotics begin, although treatment should ideally start before or alongside the first antibiotic. Starting dexamethasone the following day merely to correct an omission falls outside the beneficial timing described.
A patient completes electroconvulsive therapy and can again form new memories, but several personally important memories from before treatment remain absent. What type of memory impairment does this represent?
Retrograde amnesia. It affects memories from before treatment and can persist even after the ability to form new memories has recovered.
A patient with a durable left ventricular assist device develops hypotension and loss of arterial pulsatility. Echocardiography shows the left ventricular cavity collapsing around the pump inlet. What complication does this indicate?
This indicates an LVAD suction event. The episode describes reducing pump speed while assessing causes including hypovolaemia, right ventricular failure, tamponade and excessive pump speed.
Daily Clinical Briefings are prepared using ChatGPT Pro from the show notes and educational output for that day’s episodes. Iain Beardsell then checks the briefing for accuracy.
This describes the current briefing process. Item-specific review dates are shown only where documented. The original podcasts remain the sources; MedPod’s briefing is additional educational material.
Read about MedPod’s editorial approach
Report an error or source concern — please include the article title and link, without patient-identifying information.
.svg)